External Resources
Posted by 
Last updated and reviewed on: October 13, 2025What is CAR T-cell therapy for myeloma?
When to consider CAR T-cell therapy?
FDA-approved myeloma CAR T-cell therapies
- Carvykti Prescribing Information
- The Carvykti Treatment Process
- Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
- Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses
- FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple Myeloma
- U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
- How will I receive ABECMA?
Side effect management of CAR T-cell therapy for multiple myeloma
- Cytokine release syndrome
- Grading of cytokine release syndrome associated with the CAR T cell therapy
- Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
- CAR T-Cell Grading and Management: ICANS
- In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy
- Cytopenia after CAR-T Cell Therapy—A Brief Review of a Complex Problem
- Managing Fatigue, Anemia, and GI Side Effects with Nutrition
- Cytopenia
- Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy
- Your questions about BCMA and multiple myeloma, answered
- Recommendations on Prevention of Infections during Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma
- Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies
- Immune effector cell-associated neurotoxicity syndrome (ICANS) and other neurologic toxicities of CAR-T cell and related therapies
- Cytopenias in BCMA CAR T: unraveling inflammatory mechanisms
- Potential Side Effects of CAR T-cell Therapy: Symptoms & Treatment
- New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies
- Nausea and vomiting
A look ahead: The future of myeloma CAR T-cell therapy
- Minimally modified off-the-shelf allogeneic CAR T cells
- Allogeneic off-the-shelf CAR T-cell therapy
- New CAR T Trial in MM Aims for Triple Receptor Targeting
- Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment
- AstraZeneca pays up to $1bn for biotech firm ‘that could transform cell therapy’
Caregiver role in myeloma CAR-T
Communicating with your healthcare team
Financial resources for myeloma CAR-T
- Inpatient hospital care
- Medicare Prescription drugs (outpatient)
- What Medicare Part D drug plans cover
- Medicare Chemotherapy
- CMS Oncology Care Model
- Drugs excluded from Part D coverage
- Parts of Medicare
- Inflation Reduction Act Research Series— Medicare Part D Enrollee Out-Of-Pocket Spending: Recent Trends and Projected Impacts of the Inflation Reduction Act
- Financial Considerations for CAR T-cell Therapy Patients